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ABSTRACT
Introduction: T components of the current eighth edition
of lung cancer American Joint Commission on Cancer (AJCC)
staging assignment include size of primary tumor and
others such as chest wall invasion. The role of the presence
of multiple T3 descriptors in prognosis remains unknown.
Methods: Using the National Cancer Database and the AJCC
seventh edition, pathologically staged (R0) N0M0 NSCLC
cases diagnosed in 2010 to 2016 were analyzed. The
selected cases had primary size larger than 5 cm or staged
as T3 by the AJCC seventh edition despite the size of less
than 5 cm. T3 descriptor status according to the eighth
edition was deﬁned as single descriptor (“T3-single”) with
primary size of 5 to 7 cm or size less than 5 cm and T3
based on the seventh edition (“T3-other”) or multiple
descriptor (“T3-multi”) with presence of both descriptors.
Survival analysis was performed with validation of multivariate analyses.
Results: Of the 108,632 surgically resected pathologically
staged N0M0R0 NSCLC cases, 9931 met the following
criteria: 8955 as T3-single (4381 as T3-size, 4574 as T3other) and 884 as T3-multi. Univariate and multivariate
analyses revealed that T3-multi had signiﬁcantly worse
overall survival than T3-single with a median survival of
37.3 versus 69.3 months, respectively. Propensity score
matching analysis validated the statistical signiﬁcance.
Exploratory analysis also revealed that the survival of the
T3-multi group is similar to that of the T4 groups.
Conclusions: Our retrospective analysis using the National
Cancer Database suggests that prognosis of patients with
multiple T3 descriptors is substantially worse than those
with single descriptors. Further research may be required
to accurately deﬁne the prognosis of NSCLC for future
staging update.

 2020 The Authors. Published by Elsevier Inc. on behalf of
the International Association for the Study of Lung Cancer.
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Non–small cell lung cancer; T3; NCDB; Staging

Introduction
Despite concerted effort and technological advances
in early detection, diagnosis, and treatment, lung cancer
remains the deadliest disease among adult malignancies.
According to the U.S. National Cancer Institute’s Surveillance, Epidemiology, and End Results program, more
than 135,000 people are expected to succumb to the
disease in 2020, accounting for 22% of all cancer deaths
in the United States.1 Patient survival is largely dependent on assigned TNM stage. Lung cancer staging manuals have been published and updated every several
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years by the American Joint Committee on Cancer
(AJCC) and the Union for International Cancer Control
(UICC).2-4
AJCC/UICC staging manuals have been routinely used
as tools by clinicians to estimate survival. The most
recent edition of lung cancer staging manual (version 8)
was published in 2017 and implemented in January
2018 after thorough investigation on cases submitted by
international researchers, yielding much larger sample
size than previous versions.5,6 The accuracy and
distinction among stages in prognosis have been validated in a number of external retrospective studies.7-10
As more diagnostic and therapeutic technology develops over the next decades, the staging manuals must
be updated regularly to reﬂect the change in
management.
Regarding updates in the AJCC/UICC eighth edition of
lung cancer staging, emphasis was made on modiﬁcation
of the T component.11,12 After intense investigation in
survival estimation, tumors with a size larger than 5 cm
but not larger than 7 cm were assigned to T3 and those
larger than 7 cm were assigned to T4. Although other
nonsize descriptors deﬁning T3 were reevaluated, only
minor changes were made to reclassify T3 to T2 or T4.
Prognosis of cases with multiple T3 descriptors (e.g., size
between 5 and 7 cm and chest wall invasion) has never
been incorporated into even the AJCC/UICC eighth edition because no solid conclusion had been made from
their analysis at the time.11,12 The objective of the present study is to analyze the prognostic impact of single
and multiple T3 descriptors in pathologically staged,
completely resected NSCLC.

Materials and Methods
National Cancer Database
The National Cancer Database (NCDB) is a joint
project of the Commission on Cancer (CoC) of the
American College of Surgeons and the American Cancer
Society. The CoC’s NCDB and the hospitals participating
in the CoC NCDB are the sources of the deidentiﬁed data
used herein; however, they have not veriﬁed and are not
responsible for the statistical validity of the data analysis
or the conclusions derived by the authors. The data are
considered as hospital-based rather than populationbased.13
After obtaining approval from the CoC, access to information of deidentiﬁed cases with NSCLC was granted
in October 2019. A total of 590,891 adult cases diagnosed between 2010 and 2016 at the CoC-participating
institution in the United States were screened for this
study.
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Eligible cases must have been pathologically staged
as pN0M0 according to the AJCC/UICC seventh edition
and must have undergone R0 resection of the primary
tumor. Obtained data with the AJCC/UICC seventh edition were converted to the eighth edition as follows.
Cases with pT2 based on the AJCC/UICC seventh edition14 and a size between 5 and 7 cm would have been
assigned to pathologic T3 (pT3) on the basis of the AJCC
eighth edition11,12 and grouped as “T3-size.” Those with
pT3 and a size equal or less than 5 cm were considered
as having T3 descriptor other than size by the AJCC/
UICC seventh and eighth editions and were therefore
assigned to “T3-other.” T3 descriptors other than size,
which were not reported by NCDB, have presumably
included the following: chest wall invasion, parietal
pleura, phrenic nerve, intrapulmonary nodule in the
same lobe, parietal pericardium, main bronchus within 2
cm from carina, atelectasis, mediastinal pleura, and diaphragm. Although invasion of the diaphragm was
reclassiﬁed to T4 based on the AJCC/UICC ninth version,
it seems infrequent according to the study by Rami-Porta
et al.5 There were only 40 of 1882 cases (3%) with T3
cases (Supplementary Table 2). T3 size and T3 other
were then grouped together as “T3-single.” Those with
pT3 and a size between 5 and 7 cm were considered as
having T3 descriptor other than size by the AJCC/UICC
seventh edition and size itself deﬁnes T3 by the AJCC/
UICC eighth edition; therefore, they are grouped as “T3multi” (Supplementary Table 1). Deﬁnition of “T3” in all
the groups are based on the AJCC/UICC eighth edition. Of
note, a size between 5 and 7 cm is T2 by the AJCC/UICC
seventh edition and T3 by the AJCC/UICC eighth edition.
Cases with survival time less than one month were
removed from the ﬁnal analysis (Fig. 1).
Key clinical characteristics were obtained and
examined for association with T3-multi group. They
included age (<70 versus 70), sex (male versus female), race (White versus others), insurance status
(uninsured versus insured), institution (academic versus
others), Charlson-Deyo comorbidity score, year of diagnosis (2010–2013 versus 2014–2016), cell type
(adenocarcinoma not otherwise speciﬁed versus others),
radiation (yes versus no), multiagent chemotherapy (yes
versus no), and immunotherapy (yes versus no). Of note,
information on cancer treatment was available only for
ﬁrst-course of therapy before recurrence. Treatment
details in cases of recurrent disease were not obtained.
In an exploratory analysis, the subclassiﬁcation of T4 as
in T3 was performed. Cases with AJCC/UICC eighth edition
T4 were divided into T4-size, T4-other, and T4-multi
(Supplementary Table 1). Deﬁnition of “T3 and T4” in all
the groups are based on the AJCC/UICC eighth edition.
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N=590,891

Paents with any NSCLC diagnosed
and captured in the NCDB between 2010 and 2016

N=108,632

Staged pN0cM0 with R0 resecon

pT3 by AJCCv7
N=9,700

Primary size >7 cm
or unknown
N=4,185

3

pT2 by AJCCv7
N=34,669

Primary size >5 and ≤7 cm

Primary size <5 cm

T3 Mul
N=892

T3 Other
N=4,623

Primary size ≤ 5 cm
or unknown
N=30,253

T3 Size
N=4,416

Overall survival data available and OS ≥ 30 days
T3 Mul
N=884

T3 Other
N=4,574

T3 Size
N=4,381

T3 Single
N=8,955
NSCLC, non-small cell lung cancer; NCDB, Naonal Cancer Database; OS, overall survival; BMs, Brain metastases

Figure 1. Study ﬂow diagram of case eligibility. AJCCv7, American Joint Commission on Cancer seventh edition; NCDB,
National Cancer Database; OS, overall survival; pT2, pathologic T2; pT3, pathologic T3.

Statistics
Correlation between the clinical characteristics listed
previously and the T3 groups was determined by chisquare tests. Survival analysis was conducted using
Kaplan-Meier and log-rank methods. A p value of less
than 0.05 on a two-tailed statistical analysis was
considered signiﬁcant. Univariate and multivariate Cox
proportional hazard analyses were performed using JMP
version 14 (SAS Institute, Cary, NC). Hazard ratios with
95% conﬁdence intervals were provided. Propensity
score matching (PSM) analysis included all the variables
listed in Table 1 except insurance, race, and year of
diagnosis and was performed according to the XLSTAT
software guideline.15
This is not a population-based but a hospital-based
study that involves no identiﬁable information for individuals throughout the analyses. This study was
reviewed by the institutional review board at Parkview
Health and was designated exempt from human subject
research before beginning data analysis.

Results
Although detailed information about all the descriptors to deﬁne T3 by the seventh edition was not

available, we were able to presume that one of the
nonsize T3 descriptors was present if the case was
pathologically staged as T3 and its primary size was 5 cm
or smaller. The screening process of the candidate cases
is illustrated in Figure 1. Of the 590,891 NSCLC cases
diagnosed between 2010 and 2016, a total of 108,632
cases have undergone R0 resection with pathologic stage
of N0M0 based on the AJCC/UICC seventh edition. A total
of 9700 and 34,669 cases had pT3 and pT2, respectively.
Subsequently, 4623 pT3 cases with a primary size less
than 5 cm, 892 pT3 cases with a primary size greater
than 5 and less than or equal to 7 cm, and 4416 pT2
cases with a primary size greater than 5 and less than or
equal to 7 cm were deﬁned as T3-other, T3-multi, and
T3-size, respectively, according to the AJCC/UICC eighth
edition. Of note, a primary size greater than 5 and less
than or equal to 7 cm is deﬁned as T2 and T3 according
to the seventh and the eighth edition, respectively. A size
greater than 7 cm is deﬁned as T3 based on the seventh
edition. T3 assignment by the seventh edition despite a
primary size greater than 5 and less than or equal to 7
cm indicates presence of nonsize T3 descriptors. Therefore, those in T3-multi group have a size to deﬁne T3 by
the eighth edition (i.e., a primary size >5 and 7 cm) and
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Table 1. Characteristics of AJCCv8 Pathologic T3-Single Versus T3-Multi Descriptors According to AJCCv7 Data
Before PSM

After PSM

Factors

Single

Multiple

p Value

Total
Age, y
<70
70
Sex
Male
Female
Race
White
Others
Insurance status
Uninsured
Insured
Institution
Academic
Others
CD score
0–1
2
Year of diagnosis
2010–2013
2014–2016
Cell type
A-NOS
Others
Radiation
Yes
No
Multiagent chemotherapy
Yes
No
Immunotherapy
Yes and No

N ¼ 8955 (100%)

N ¼ 884 (100%)

Single

Multiple

N ¼ 884

N ¼ 884

502 (57)
382 (43)

502 (57)
382 (43)

498 (56)
386 (44)

498 (56)
386 (44)

783 (89)
101 (11)

789 (89)
95 (11)

10 (1)
874 (99)

35 (4)
849 (96)

367 (42)
517 (58)

368 (42)
516 (58)

746 (84)
138 (16)

743 (84)
141 (16)

571 (65)
313 (35)

585 (66)
299 (34)

219 (25)
665 (75)

220 (25)
664 (75)

233 (26)
651 (74)

233 (26)
651 (74)

459 (52)
425 (48)

459 (52)
425 (48)

884 (100%)

884 (100%)

0.0288
4741 (53)
4214 (47)

502 (57)
382 (43)

4632 (52)
4323 (48)

498 (56)
386 (44)

7885 (88)
1070 (12)

789 (89)
95 (11)

146 (2)
8809 (98)

35 (4)
849 (96)

3782 (42)
5173 (55)

368 (42)
516 (58)

7456 (83)
1499 (17)

743 (84)
141 (16)

5941 (66)
3014 (34)

585 (66)
299 (34)

2862 (32)
6093 (68)

220 (25)
664 (75)

771 (9)
8184 (91)

233 (26)
651 (74)

3146 (35)
5809 (65)

459 (52)
425 (48)

8955 (100%)

884 (100%)

p Value
1.0000

0.0089

1.0000

0.2913

0.6495

<0.0001

0.0002

0.7285

0.9615

0.5482

0.8448

0.9205

0.4840

<0.0001

0.9561

<0.0001

1.0000

<0.0001

1.0000

0.9311

0.5634

AJCCv7, American Joint Commission on Cancer seventh edition; AJCCv8, American Joint Commission on Cancer eighth edition; A-NOS, adenocarcinoma not
otherwise speciﬁed; CD, Charlson-Deyo; PSM, propensity score matching.
Due to agreement with National Cancer Database, reporting cells <10 cases is prohibited. They were combined with the opposing cells.

a nonsize T3 descriptor. After removing cases with
overall survival less than 1 month, 4574, 884, and 4381
patients were analyzed further, respectively.
The characteristics of the T3 groups according to the
AJCC/UICC eighth edition are illustrated in Table 1. Before
PSM, presence of multiple descriptors (T3-multi group)
was signiﬁcantly associated with younger age (p ¼ 0.0288),
male sex (p ¼ 0.0089), uninsured status (p < 0.0001),
history other than adenocarcinoma not otherwise speciﬁed
(p < 0.0001), radiation therapy (p < 0.0001), and multiagent chemotherapy (p < 0.0001). After adjustment with
PSM, all factors except uninsured status (p ¼ 0.0002) had
no signiﬁcant association with the T3-multi group.
Analysis on overall survival revealed that the T3multi group had a signiﬁcantly worse survival than
T3-size and T3-other, with hazard ratios of 0.65 and

0.58, respectively (Fig. 2A). The magnitude of difference in survival between T3-size and T3-other was
comparatively smaller with a hazard ratio of 0.89.
When T3-size and T3-other were grouped together as
T3-single, a signiﬁcantly better survival than T3-multi
was also found with median overall survivals of 69.3
versus 37.3 months, respectively (Fig. 2B). This difference was statistically signiﬁcant, as univariate and
multivariate analyses revealed that T3-single status
had a signiﬁcantly longer overall survival than the T3multi group with a hazard ratio of 0.61 and 0.62,
respectively (Table 2). Other clinical groups with
signiﬁcantly longer survival in multivariate analysis
included younger age, female, academic institution, low
Charlson-Deyo comorbidity score, lack of radiation, and
multiagent chemotherapy.
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T3-other
T3-size
T3-multi

N
4574
4381
884

N
8955
884

T3-single
T3-multi

mOS (months)
69.3
37.3

p-value HR (95% CI)
0.0009 0.89 (0.83–0.95)
<0.0001 0.58 (0.52–0.65)
<0.0001 0.65 (0.59–0.73)

Logrank
p < 0.0001
HR (95% CI) 0.61 (0.56–0.68)

Surviving

Surviving

Logrank
T3-other versus T3-size
T3-other versus T3-multi
T3-size versus T3-multi

web 4C=FPO

B

mOS (months)
72.9
66.8
37.3

5

Months
At risk (Year) 0
1
2
3
4
5
6
T3-other
4574 3794 2988 2097 1408 847 397
T3-size
4381 3516 2703 1913 1314 792 373
T3-multi
884 673 440 295 184 110 49

Months
7
107
98
12

At risk (Year) 0
T3-single
T3-multi

1

2

3

4

5

6

8955 7310 5689 4008 2722 1638 770
884 673 440 295 184 110 49

7
204
12

Figure 2. Overall survival according to AJCCv8 T3 descriptor status. Survival curves were plotted according to T3 status.
Numbers of cases at risk are revealed for each calendar year. (A) Survival curves for T3-other, T3-size, and T3-multi. (B)
Survival curves for T3-single and T3-multi. AJCCv8, American Joint Commission on Cancer eighth edition; CI, conﬁdence
interval; HR, hazard ratio; mOS, median overall survival.

PSM analysis also supported the above-mentioned
ﬁnding that the T3-multi group has reduced overall
survival. With a hazard ratio of 0.66, median survivals
were 66.3 and 37.3 months in T3-single versus T3-multi,
respectively (Fig. 3). Multivariate analysis on the cases
selected for PSM revealed that groups with younger age,
female, low Charlson-Deyo comorbidity score, lack of
radiation, multiagent chemotherapy, and T3-single status had signiﬁcantly longer survival time (Table 2,
Supplementary Fig. 1).
As an exploratory analysis, survival curves of the T3
subgroups were compared with those of the T4 subgroups (Supplementary Fig. 1). Survival of the T3-multi
group was similar to the T4 subgroups, and even
worse than the T4-size/other.

Discussion
To estimate the prognosis of patients diagnosed with
cancer, cancer staging systems have been developed
over the past several decades.2,3 They are useful tools for
providing clinicians and patients with information
necessary to determine therapeutic intervention. As
novel technology develops, these staging systems need
to be adjusted to reﬂect the current diagnosis and
therapeutic interventions. For lung cancer, new diagnostic and therapeutic modalities over the past few decades include positron emission tomography scan,
endobronchial ultrasound, intensity-modulated radiation
therapy/stereotactic body radiation therapy, roboticassisted surgery, and others. Staging systems were
built and updated periodically with recent cases registered for this purpose.

The AJCC/UICC eighth edition lung cancer staging
was revolutionary in several aspects. The committee
recruited 94,708 cases that were diagnosed to have lung
cancer between 1999 and 2010 from 35 sources in 16
countries. This was a remarkable increase in sample size
from the sixth edition in 1997 with 5319 cases.16
The AJCC/UICC eighth edition committee proposed to
divide T1–2 into small subsets on the basis of primary
tumor size, revealing notable separation in survival between the T subgroups.11 It allowed estimation of each
patient’s survival more precisely. The deﬁnition of T3
and T4 was also revisited. A tumor size larger than 7 cm
was reclassiﬁed from T3 to T4, and those between 5 and
7 cm were assigned from T2 to T3. Nonsize T descriptors
were reconsidered; invasion to the diaphragm was
upstaged to T4, whereas main bronchus lesion within 2
cm and total atelectasis were downstaged to T2
(Supplementary Table 2).11
The nonsize T descriptors are uncommonly reported.
According to Rami-Porta et al.,11 less than 10% overall
were deﬁned as T3 with the AJCC/UICC seventh edition.
Jeon et al.17 in Korea conducted a single institutional
retrospective analysis to review cases diagnosed to have
pT3 according to the AJCC/UICC seventh edition between 2001 and 2013. They reported that the T3-multi
group with 63 patients had an inferior survival as
compared with other T3 groups. Their small sample size
limited its signiﬁcance as a poor prognostic indicator.
The role of coexisting size and nonsize T3 descriptors
in comparison with a single descriptor remained unclear.
To address the signiﬁcance of multiple T3 descriptors,
we conducted a retrospective analysis with cases obtained from NCDB. Patients with pathologically staged T2
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Table 2. AJCCv8 Pathologic T3-Single Versus T3-Multi Descriptors According to AJCCv7 Data. Overall Survival Analysis

Factors
Age, y
<70
70
Sex
Female
Male
Race
Others
Whites
Insurance status
Uninsured
Insured
Institution
Academic
Others
CD score
0–1
2
Year of diagnosis
2014–2016
2010–2013
Cell type
A-NOS
Others
Radiation
No
Yes
Multiagent chemotherapy
Yes
No
Immunotherapy
Yes
No
T3 status
Single
Multiple

Before PSM

After PSM

N ¼ 8599 vs. 884

N ¼ 884 vs. 884

Univariate

Multivariable

Univariate

Multivariable

HR (95% CI)

HR (95% CI)

HR (95% CI)

HR (95% CI)

p Value

p Value

p Value

p Value

0.63 (0.59–0.67)
<0.0001

0.68 (0.63–0.72)
<0.0001

0.69 (0.59–0.80)
<0.0001

0.64 (0.55–0.73)
<0.0001

0.69 (0.65–0.74)
<0.0001

0.73 (0.68–0.78)
<0.0001

0.70 (0.60–0.81)
<0.0001

0.76 (0.65–0.88)
0.0002

0.88 (0.79–0.97)
0.0114

0.97 (0.87–1.07)
0.5296

1.01 (0.79–1.26)
0.9546

1.07 (0.84–1.34)
0.5676

0.89 (0.69–1.12)
0.3254

1.03 (0.81–1.32)
0.7838

1.28 (0.84–1.87)
0.2400

1.42 (0.95–2.14)
0.0876

0.79 (0.74–0.84)
<0.0001

0.80 (0.75–0.86)
<0.0001

0.87 (0.75–1.00)
0.0536

0.90 (0.78–1.04)
0.1712

0.75 (0.69–0.81)
<0.0001

0.81 (0.74–0.88)
<0.0001

0.67 (0.56–0.80)
<0.0001

0.72 (0. 60–0.86)
0.0004

0.95 (0.87–1.03)
0.1855

0.96 (0.89–1.05)
0.3736

1.03 (0.87–1.22)
0.6995

1.06 (0.89–1.25)
0.5298

0.87 (0.81–0.93)
0.0001

0.93 (0.87–1.00)
0.0518

0.84 (0.71–0.99)
0.0390

0.92 (0.78–1.09)
0.3509

0.72 (0.66–0.80)
<0.0001

0.64 (0.58–0.71)
<0.0001

0.77 (0.66–0.90)
0.0009

0.60 (0.51–0.71)
<0.0001

0.68 (0.63–0.73)
<0.0001

0.67 (0.62–0.72)
<0.0001

0.68 (0.59–0.78)
<0.0001

0.66 (0.56–0.77)
<0.0001

0.90 (0.39–1.75)
0.7870

1.02 (0.49–2.15)
0.9507

0.60 (0.03–2.66)
0.5800

1.00 (0.14–7.13)
0.9980

0.61 (0.56–0.68)
<0.0001

0.62 (0.56–0.69)
<0.0001

0.66 (0.57–0.76)
<0.0001

0.66 (0.58–0.77)
<0.0001

AJCCv7, American Joint Commission on Cancer seventh edition; AJCCv8, American Joint Commission on Cancer eighth edition; A-NOS, adenocarcinoma not
otherwise speciﬁed; CD, Charlson-Deyo; CI, conﬁdence interval; HR, hazard ratio; PSM, propensity score matching.

to T3N0M0 according to the AJCC seventh edition were
selected and reassigned to T3 based on the AJCC/UICC
eighth edition. They were further classiﬁed into T3-single
(T3-size þ T3-other) and T3-multi based on the abovementioned criteria (Supplementary Table 1). Survival of
the T3-multi group was signiﬁcantly shorter than that of
the T3-single, and this statistical signiﬁcance held true
after PSM analyses. The T3-multi group was similar to the
T4-multi group, and both groups had worse overall survival than other T4 subgroups. Our ﬁndings suggest that

the T3-multi group may be reassigned to or grouped
together with T4 subgroups.
Although our data suggest a novel approach and
ﬁnding for staging amendment expected in coming years,
we acknowledge several limitations. First, our analyses
rely on the database that collected information in CoCparticipating institutions. It is possible that there might
be reporting errors and misclassiﬁcation in staging
assignment. Owing to deidentiﬁed data, it is impossible
to collect information that was not recorded previously.

March 2021

T3 Descriptors in Lung Cancer Staging

T3-single
T3-multi

N
8955
884

mOS (months)
66.3
37.3

web 4C=FPO

Surviving

Logrank
p < 0.0001
HR (95% CI) 0.66 (0.57–0.76)
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Figure 3. Overall survival according to AJCCv8 T3 descriptor
status. Propensity score matching analysis for single versus
multiple T3 descriptors. AJCCv8, American Joint Commission
on Cancer eighth edition; CI, conﬁdence interval; HR, hazard
ratio; mOS, median overall survival.

Second, staging methods used in the cases are not
available. Although all the cases underwent surgical and
pathologic staging, surveys for metastasis may not be
consistent. Cases in recent years might have undergone
more advanced techniques such as positron emission
tomography and endobronchial ultrasound. Difference in
surgical technique has not been addressed in this study.
Third, we focused on surgically resected, pathologically staged T3N0M0 cases. The roles of the multiple
descriptors in node-positive cases or clinically staged
T3N0 cases were not investigated. This is to minimize
inﬂuence by nodal status and presence/absence of surgery, respectively.
Finally and perhaps more importantly, there are
several modiﬁcations in T3 when updated to the AJCC/
UICC eighth edition. Beside size criteria, several factors
to deﬁne T3 by the AJCC/UICC seventh edition were
reassigned to T2 or T4 (Supplementary Table 2). NCDB
does not provide all the descriptions regarding T3
assignment. However, according to a comprehensive
study conducted by the eighth edition staging working
group, only 6% and 3% of single T3 descriptor cases
were downstaged and upstaged because of any reason
other than size criteria, respectively (Supplementary
Table 2),11 suggesting the vast majority of cases
assigned to T3 by the AJCC/UICC seventh edition can still
be assigned to T3 by the AJCC/UICC eighth edition.
In conclusion, our retrospective study of a large
sample size indicates that pathologically staged T3N0M0
NSCLCs deﬁned by single and multiple descriptors have
different prognoses. This ﬁnding is relevant in clinical
practice to reﬁne postoperative prognosis, and it should
be taken into consideration, pending clinical and
external validations, in the preparation of the forthcoming AJCC/UICC ninth edition for lung cancer.
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